Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Controversies in the Management of Proximal Deep Vein Thrombosis

Toby Richards

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Review of Coronary Artery Calcium Testing for Primary Care

Dr. Catherine P. Benziger

C. Benziger

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

Hypertension 2025: New Guidelines and Resistant Hypertension

University of Louisville

K. Ferdinand

The Role of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Pediatr…

ISPAD's 50th Annual Conference 2024

A. Sanghavi

Anti-Obesity Medications

Michigan Medicine

D. H. Griauzde